AbCellera and Denali Therapeutics Expand Collaboration to Develop Abs for Neurological Disorders
Shots:
- AbCellera to receive technology access fee- milestones and royalties on the development and commercialization of pre-cliniocal candidates & will develop Abs for Denali’s eight targets for neurological disorders
- On 12 Jun-2018 Denali therapeutics collaborated with AbCellera for its single-cell technology to develop hundreds of mAbs for neurodegenerative diseases
- AbCellera’s single-cell screening technology is a combination of live-cell assays to develop therapies for targets such as membrane proteins- GPCRs and ion channels in multiple therapy areas
Ref: AbCellera | Image: Evaluating Pharmacy
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
